Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12695539
Gonzalez-Cabrera PJ, et al. (2003) Genetic profiling of alpha 1-adrenergic receptor subtypes by oligonucleotide microarrays: coupling to interleukin-6 secretion but differences in STAT3 phosphorylation and gp-130. Mol Pharmacol 63, 1104-16 12695539
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y705-p - STAT3 (rat)
Modsite: DPGSAAPyLKTKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  Rat1 (fibroblast) [ADRA1A (human)], Rat1 (fibroblast) [ADRA1B (human)], Rat1 (fibroblast) [ADRA1D (human)]
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine ADRA1A (human) increase
anti-IL-6 racepinefrine ADRA1A (human) no effect upon treatment-induced increase
IL-6 ADRA1A (human) increase
anti-IL-6 IL-6 ADRA1A (human) inhibit treatment-induced increase
racepinefrine IL-6 ADRA1A (human) augment treatment-induced increase
racepinefrine ADRA1B (human) increase
anti-IL-6 racepinefrine ADRA1B (human) no effect upon treatment-induced increase
IL-6 ADRA1B (human) increase
anti-IL-6 IL-6 ADRA1B (human) inhibit treatment-induced increase
racepinefrine IL-6 ADRA1B (human) augment treatment-induced increase
racepinefrine ADRA1D (human) increase
anti-IL-6 racepinefrine ADRA1D (human) no effect upon treatment-induced increase
IL-6 ADRA1D (human) increase
anti-IL-6 IL-6 ADRA1D (human) inhibit treatment-induced increase
racepinefrine IL-6 ADRA1D (human) augment treatment-induced increase

S727-p - STAT3 (rat)
Modsite: NTIDLPMsPRTLDSL SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 iso3 (human): , STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): , STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  Rat1 (fibroblast) [ADRA1A (human)], Rat1 (fibroblast) [ADRA1B (human)], Rat1 (fibroblast) [ADRA1D (human)]
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine ADRA1A (human) increase
IL-6 ADRA1A (human) increase
racepinefrine IL-6 ADRA1A (human) no effect upon treatment-induced increase
racepinefrine ADRA1B (human) increase
IL-6 ADRA1B (human) increase
racepinefrine IL-6 ADRA1B (human) no effect upon treatment-induced increase
racepinefrine ADRA1D (human) increase
IL-6 ADRA1D (human) increase
racepinefrine IL-6 ADRA1D (human) inhibit treatment-induced increase